Loading data for BCYC — first visit, this takes a few seconds.

Bicycle Therapeutics

NasdaqGS: BCYC · Real-Time Price · USD
4.20
-0.13 (-3.00%)
At close: Aug 28, 2026, 8:00 PM
4.20
+0.00%
After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

Bicycle Therapeutics (BCYC) Stock Price, Analysis & Data

-3.00%

No data available

Bid3.04
Market Cap293.97M
Revenue (ttm)61.2M
Net Income (ttm)-190.41M
1.53
-2.73
n/a
-1.89
P/B (ttm)0.57
P/S (ttm)4.79
Earnings DateOct 29, 2026
Ask4.21
Volume154,684
Avg. Volume (20D)424,050
Open4.32
Previous Close4.33
Day's Range4.19 - 4.33
52-Week Range3.75 - 9.16
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About BCYC

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clin...

Industry Biotechnology
Sector Healthcare
IPO Date May 23, 2019
Employees 288
Stock Exchange NasdaqGS
Ticker Symbol BCYC
Full Company Profile

Financial Performance

In 2025, Bicycle Therapeutics's revenue was 72.59M, an increase of 105.77% compared to the previous year's 35.27M. Earnings were -218.96M, an increase of 29.54%.

Financial Statements

Earnings Surprise

Bicycle Therapeutics has released their quarterly earnings on Jul 30, 2026:
  • Revenue of $629K misses estimates by $0, with -78.46% YoY decline.
  • EPS of -0.72 misses estimates by -0.14, with 36.84% YoY growth.
Bicycle Therapeutics is scheduled to release its earnings on Oct 29, 2026, before market opens.
Analysts project revenue of ... Upgrade